TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
暂无分享,去创建一个
Scott L. Pomeroy | Robert J. Wechsler-Reya | Stefan M. Pfister | Paul A. Northcott | Andreas von Deimling | Andrey Korshunov | Nada Jabado | David T. W. Jones | Uri Tabori | Reid C. Thompson | William A. Weiss | Boleslaw Lach | Michael K. Cooper | Franck Bourdeaut | Darell D. Bigner | Eric Bouffet | Roger E. McLendon | Ian F. Pollack | Stefan Rutkowski | László Bognár | Xin Wang | Johan M. Kros | Seung-Ki Kim | Joshua B. Rubin | Christian Koelsche | Anne Jouvet | Annie Huang | Ulrich Schüller | Marcel Kool | Pim J. French | Stephen C. Mack | Vijay Ramaswamy | Maryam Fouladi | Livia Garzia | R. McLendon | Erwin G. Van Meir | S. Croul | M. Kool | D. Bigner | L. Liau | J. Mora | P. Northcott | S. Pfister | Shin Jung | J. Rutka | C. Hawkins | S. Pomeroy | I. Pollack | A. von Deimling | U. Schüller | Yoon-Jae Cho | A. Jouvet | A. Korshunov | R. Wechsler-Reya | W. Weiss | P. French | J. Kros | A. Morrissy | S. Albrecht | P. Hauser | M. Garami | A. Klekner | L. Bognár | M. Remke | P. Dirks | Michael D. Taylor | A. Huang | N. Jabado | D. Malkin | C. Eberhart | W. Grajkowska | A. Dubuc | S. Agnihotri | Xiaochong Wu | S. Rutkowski | R. Thompson | C. Carlotti | S. Mack | F. Bourdeaut | M. Zollo | L. Garzia | D. Shih | F. Cavalli | V. Ramaswamy | Xin Wang | J. Peacock | C. Faria | D. Fults | L. Massimi | K. Zitterbart | Y. Ra | M. K. Cooper | U. Tabori | E. Bouffet | R. Vanner | Seung-Ki Kim | M. Fouladi | C. Koelsche | M. Perek-Polnik | F. Doz | M. Fèvre-Montange | B. Lach | S. Elbabaa | J. Leonard | J. Rubin | A. Saad | R. Vibhakar | T. Van Meter | M. Barszczyk | O. Delattre | Marc Remke | Betty Luu | Yoon-Jae Cho | Marta Perek-Polnik | Jaume Mora | Michelle Fèvre-Montange | Karel Zitterbart | Almos Klekner | Peter Hauser | Shin Jung | Luca Massimi | Rajeev Vibhakar | David Meyronet | James T. Rutka | Sameer Agnihotri | Jennifer A. Chan | Linda M. Liau | David Malkin | D. Meyronet | A. Sorana Morrissy | Florence M. G. Cavalli | Xiaochong Wu | Peter B. Dirks | Massimo Zollo | Charles G. Eberhart | Miklós Garami | John Peacock | Steffen Albrecht | Carlos G. Carlotti | David J. H. Shih | Nadia Hill | Mark Barszczyk | Adrian M. Dubuc | Nataliya Zhukova | Robert Vanner | Ali G. Saad | Oliver O. Delattre | François F. Doz | Timothy E. Van Meter | Daniel Fults | Toshiro Kumabe | Young Shin Ra | Jeffrey R. Leonard | Samer K. Elbabaa | Claudia C. Faria | Sidney E. Croul | Cynthia E. Hawkins | Wieslawa A. Grajkowska | N. Zhukova | J. Chan | B. Luu | N. Hill | Toshiro Kumabe | M. Perek‐polnik | Á. Klekner | L. Bognár | Seung-Ki Kim | J. Leonard | Rajeev Vibhakar | Timothy Van Meter
[1] Matthew J. Betts,et al. Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.
[2] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[3] P. Northcott,et al. Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. , 2010, Neurosurgical focus.
[4] Elaine R. Mardis,et al. Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.
[5] E. Hiyama,et al. Telomere and telomerase in stem cells , 2007, British Journal of Cancer.
[6] David T. W. Jones,et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. , 2013, The Lancet. Oncology.
[7] D. Schadendorf,et al. Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .
[8] Zev A. Binder,et al. The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.
[9] Axel Benner,et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Scott L. Pomeroy,et al. Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.
[11] Dirk Troost,et al. Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.
[12] M. Kool,et al. Molecular diagnostics of CNS embryonal tumors , 2010, Acta Neuropathologica.
[13] J. Mesirov,et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Bishop,et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. , 2013, Endocrine-related cancer.
[15] C B Harley,et al. Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.
[16] M. Blasco. Telomeres and human disease: ageing, cancer and beyond , 2005, Nature Reviews Genetics.
[17] Gary L. Gallia,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.
[18] Steven J. M. Jones,et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.
[19] J. Shay,et al. Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. , 2002, Differentiation; research in biological diversity.
[20] D. Figarella-Branger,et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.
[22] I. Weissman,et al. Telomerase activity in hematopoietic cells is associated with self-renewal potential. , 1996, Immunity.
[23] S. Keir,et al. Busulfan therapy of central nervous system xenografts in athymic mice , 2004, Cancer Chemotherapy and Pharmacology.
[24] Paul A. Northcott,et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct , 2011, Acta Neuropathologica.
[25] E. Montgomery,et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. , 2011, The American journal of pathology.
[26] S. Croul,et al. Adult medulloblastoma comprises three major molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] David T. W. Jones,et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. , 2013, The Lancet. Oncology.
[28] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.
[29] Paul A. Northcott,et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma , 2009, Nature Genetics.
[30] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[31] Scott L. Pomeroy,et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples , 2011, Acta Neuropathologica.
[32] Miguel Melo,et al. Frequency of TERT promoter mutations in human cancers , 2013, Nature Communications.
[33] P. Northcott,et al. FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. , 2011, Cancer genetics.
[34] P. Kleihues,et al. TERT promoter mutations in primary and secondary glioblastomas , 2013, Acta Neuropathologica.
[35] K. Ichimura,et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss , 2013, Acta Neuropathologica.
[36] Jill P. Mesirov,et al. MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.
[37] D. Schadendorf,et al. TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.
[38] G. Reifenberger,et al. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] David T. W. Jones,et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Stefan M. Pfister,et al. The clinical implications of medulloblastoma subgroups , 2012, Nature Reviews Neurology.
[41] T. Curran,et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Hendrik Witt,et al. Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] P. Northcott,et al. The Genetics of Pediatric Brain Tumors , 2010, Current neurology and neuroscience reports.
[44] David T. W. Jones,et al. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma , 2012, Acta Neuropathologica.